ABBV

Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.

JPMorgan expects healthcare ETF flows to reverse, suggesting renewed interest in the sector. Eli Lilly and AbbVie could benefit from this potential rotation.

Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

Moderna’s overnight jump highlights a possible trend for other healthcare names. AbbVie is mentioned alongside Moderna and Pharvaris as part of a broader healthcare setup.

The cosmetic surgery market is growing fast among Americans aged 65 and older, driven by anti‑aging demand.

The article lists dividend stocks that could provide long‑term income, including a dividend king.

ANI Pharmaceuticals added Henry Gosebruch, a former AbbVie executive, to its board, while a current board member steps down but stays in operations.

The piece compares AbbVie and Pfizer, noting AbbVie’s shift to immunology and Pfizer’s lower valuation amid patent concerns.